KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Shares Outstanding (Diluted Average): 2010-2025

Historic Shares Outstanding (Diluted Average) for Halozyme Therapeutics (HALO) over the last 10 years, with Sep 2025 value amounting to $124.4 million.

  • Halozyme Therapeutics' Shares Outstanding (Diluted Average) fell 4.37% to $124.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.4 million, marking a year-over-year decrease of 4.37%. This contributed to the annual value of $129.4 million for FY2024, which is 3.56% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Shares Outstanding (Diluted Average) of $124.4 million as of Q3 2025, which was down 0.80% from $125.5 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $148.5 million for Q1 2021, and its period low was $124.4 million during Q3 2025.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $129.4 million (2024), whereas its average is $130.7 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Shares Outstanding (Diluted Average) increased by 8.28% in 2021 and then fell by 6.54% in 2024.
  • Halozyme Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $146.8 million in 2021, then fell by 4.22% to $140.6 million in 2022, then fell by 4.56% to $134.2 million in 2023, then dropped by 3.56% to $129.4 million in 2024, then fell by 4.37% to $124.4 million in 2025.
  • Its last three reported values are $124.4 million in Q3 2025, $125.5 million for Q2 2025, and $126.6 million during Q1 2025.